ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.125,51
1,74%
S&P 500
5.969,34
0,35%
US Dollar vs BRL
5,801
0,00%
Bitcoin
98.147,00
0,37%
Brent Oil
74,65
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) Notícias

RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNAZ
DataHoraFonteTítuloCódigoCompanhia
13/11/202418:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
12/11/202409:00GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
06/11/202418:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
06/11/202418:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
05/11/202409:00GlobeNewswire Inc.TransCode Therapeutics Announces Nasdaq Extension to Regain ComplianceNASDAQ:RNAZTransCode Therapeutics Inc
28/10/202417:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
23/10/202408:00GlobeNewswire Inc.TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety DataNASDAQ:RNAZTransCode Therapeutics Inc
15/10/202418:23Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
10/10/202408:00GlobeNewswire Inc.TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted TechnologyNASDAQ:RNAZTransCode Therapeutics Inc
17/09/202408:00GlobeNewswire Inc.TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic CandidateNASDAQ:RNAZTransCode Therapeutics Inc
10/09/202408:00GlobeNewswire Inc.TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic CancerNASDAQ:RNAZTransCode Therapeutics Inc
05/09/202408:00GlobeNewswire Inc.TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateNASDAQ:RNAZTransCode Therapeutics Inc
15/08/202408:00GlobeNewswire Inc.TransCode Therapeutics Announces Phase 1 Clinical Trial InitiationNASDAQ:RNAZTransCode Therapeutics Inc
14/08/202417:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAZTransCode Therapeutics Inc
26/07/202417:05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202417:05GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Closing of Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202409:18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAZTransCode Therapeutics Inc
22/07/202423:30GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Pricing of Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
22/07/202417:07GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common StockNASDAQ:RNAZTransCode Therapeutics Inc
18/06/202417:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
14/06/202409:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
10/06/202408:00GlobeNewswire Inc.Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
29/05/202410:15GlobeNewswire Inc.TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
20/05/202417:00Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RNAZTransCode Therapeutics Inc
15/04/202410:00GlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
03/04/202410:10GlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
28/03/202409:30GlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
11/03/202410:00GlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
06/03/202418:15GlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
20/02/202410:00GlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNAZ

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
ATOM3
ATOMPAR ON
BOV
COGN3
COGNA ON
BOV
ETER3
ETERNIT ON
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados